Celcuity, Inc.

As of October 10, 2025, Celcuity, Inc. shows a mildly bullish trend with mixed technical indicators, having significantly outperformed the S&P 500 year-to-date with a return of 251.95% compared to 11.41%.

As of October 10, 2025, Celcuity, Inc. has a mildly bullish trend influenced by mixed technical indicators, significantly outperforming the S&P 500 with a year-to-date return of 251.95% compared to 11.41%.

As of July 28, 2025, Celcuity, Inc. has a bullish technical trend supported by multiple indicators, despite bearish RSI signals, and has outperformed the S&P 500 with a year-to-date return of 320.40% compared to 12.22%.

As of June 6, 2025, Celcuity, Inc. shows a mildly bearish trend due to daily moving averages and weekly Dow Theory, despite mixed signals from MACD and RSI, indicating cautious bearish sentiment in the short term.

Celcuity, Inc. is a cellular analysis company focused on identifying new cancer sub-types and developing diagnostic tests to enhance treatment outcomes for cancer patients. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $446 million and reported a net profit loss of $37 million as of March 2025.

As of Jun 18, Celcuity, Inc. has a market capitalization of 446.07 million, with net sales of 0.00 million and a net profit of -127.16 million over the latest four quarters. Shareholder's funds are reported at 115.62 million, and total assets amount to 245.12 million.